This Article Full Text Full Text (PDF) All Versions of this Article: 110/7/856    most recent 01.CIR.0000138743.09012.93v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haendeler, J. Articles by Dimmeler, S. Search for Related Content PubMed PubMed Citation Articles by Haendeler, J. Articles by Dimmeler, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antioxidants Hazardous Substances DB ATORVASTATIN CYSTEINE HEPTANOIC ACID LOVASTATIN NITRIC OXIDE PYRROLE Related Collections Oxidant stress Endothelium/vascular type/nitric oxide Cell signalling/signal transduction

(Circulation. 2004;110:856-861.)
© 2004 American Heart Association, Inc.

Original Articles

Antioxidant Effects of Statins via S-Nitrosylation and Activation of Thioredoxin in Endothelial Cells

A Novel Vasculoprotective Function of Statins

From Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany.

Correspondence to Stefanie Dimmeler, PhD, Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Theodor Stern-Kai 7, 60590 Frankfurt, Germany. E-mail Dimmeler{at}em.uni-frankfurt.de

Received October 6, 2003; de novo received December 19, 2003; revision received April 8, 2004; accepted April 12, 2004.

Background— HMG-CoA reductase inhibitors (statins) are lipid-lowering drugs that also exert pleiotropic vasculoprotective effects via activation of the endothelial NO synthesis. NO induces S-nitrosylation of target proteins. S-Nitrosylation of the antioxidant enzyme thioredoxin was recently shown to enhance its activity, thereby reducing intracellular reactive oxygen species. Therefore, we investigated whether statins may exert an antioxidant activity in endothelial cells via S-nitrosylation of thioredoxin.

Methods and Results— Statins dose- and time-dependently increased the overall level of S-nitrosylated proteins in endothelial cells (atorvastatin 0.1 µmol/L, 206±30% increase; simvastatin 1 µmol/L, 214±19% increase; mevastatin 1 µmol/L, 191±10% increase). The increased S-nitrosylation was blocked by an NO-synthase inhibitor and mevalonate. Moreover, S-nitrosylation of thioredoxin was also significantly augmented after atorvastatin treatment. The atorvastatin-mediated increase in S-nitrosylation was associated with an enhanced enzymatic activity of thioredoxin (atorvastatin, 157±9% increase). This resulted in a significant reduction of intracellular reactive oxygen species within the endothelial cells. In contrast, in endothelial cells overexpressing a thioredoxin construct in which the S-nitrosylation acceptor amino acid cysteine 69 was replaced by serine [TRX(C69S)], atorvastatin did not activate the redox-regulatory activity of thioredoxin. Moreover, overexpression of the non-nitrosylatable thioredoxin TRX(C69S) abolished atorvastatin-mediated reduction of reactive oxygen species.

Conclusions— Here, we demonstrate a novel antioxidant mechanism by which statins reduce reactive oxygen species in endothelial cells. Statin-mediated S-nitrosylation of thioredoxin enhanced the enzymatic activity of thioredoxin, resulting in a significant reduction in intracellular reactive oxygen species.

Key Words: antioxidants • nitric oxide • endothelium

This article has been cited by other articles:

				L. Guasti, F. Marino, M. Cosentino, R. C. Maio, E. Rasini, M. Ferrari, L. Castiglioni, C. Klersy, G. Gaudio, A. M. Grandi, et al. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up Eur. Heart J., May 1, 2008; 29(9): 1118 - 1126. [Abstract] [Full Text] [PDF]

				P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]

				Y.-M. Go, P. J. Halvey, J. M. Hansen, M. Reed, J. Pohl, and D. P. Jones Reactive Aldehyde Modification of Thioredoxin-1 Activates Early Steps of Inflammation and Cell Adhesion Am. J. Pathol., November 1, 2007; 171(5): 1670 - 1681. [Abstract] [Full Text] [PDF]

				Y. Hoshino, T. Nakamura, A. Sato, M. Mishima, J. Yodoi, and H. Nakamura Neurotropin Demonstrates Cytoprotective Effects in Lung Cells through the Induction of Thioredoxin-1 Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 438 - 446. [Abstract] [Full Text] [PDF]

				T.-a. Okabe, K. Shimada, M. Hattori, T. Murayama, M. Yokode, T. Kita, and C. Kishimoto Swimming reduces the severity of atherosclerosis in apolipoprotein E deficient mice by antioxidant effects Cardiovasc Res, June 1, 2007; 74(3): 537 - 545. [Abstract] [Full Text] [PDF]

				A. J Bank, A. S Kelly, D. R Kaiser, W. W Crawford, B. Waxman, D. A Schow, and K. L Billups The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction Vascular Medicine, November 1, 2006; 11(4): 251 - 257. [Abstract] [PDF]

				J. Chen and J. L. Mehta Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1738 - H1745. [Abstract] [Full Text] [PDF]

				L. Tao, X. Jiao, E. Gao, W. B. Lau, Y. Yuan, B. Lopez, T. Christopher, S. P. RamachandraRao, W. Williams, G. Southan, et al. Nitrative Inactivation of Thioredoxin-1 and Its Role in Postischemic Myocardial Apoptosis Circulation, September 26, 2006; 114(13): 1395 - 1402. [Abstract] [Full Text] [PDF]

				D. E. Handy and J. Loscalzo Nitric Oxide and Posttranslational Modification of the Vascular Proteome: S-Nitrosation of Reactive Thiols Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1207 - 1214. [Abstract] [Full Text] [PDF]

				S. Fichtlscherer, C. Schmidt-Lucke, S. Bojunga, L. Rossig, C. Heeschen, S. Dimmeler, and A. M. Zeiher Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy Eur. Heart J., May 2, 2006; 27(10): 1182 - 1190. [Abstract] [Full Text] [PDF]

				J. Schwartz, S. K. Park, M. S. O'Neill, P. S. Vokonas, D. Sparrow, S. Weiss, and K. Kelsey Glutathione-S-Transferase M1, Obesity, Statins, and Autonomic Effects of Particles: Gene-by-Drug-by-Environment Interaction Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1529 - 1533. [Abstract] [Full Text] [PDF]

				U. Landmesser, F. Bahlmann, M. Mueller, S. Spiekermann, N. Kirchhoff, S. Schulz, C. Manes, D. Fischer, K. de Groot, D. Fliser, et al. Simvastatin Versus Ezetimibe: Pleiotropic and Lipid-Lowering Effects on Endothelial Function in Humans Circulation, May 10, 2005; 111(18): 2356 - 2363. [Abstract] [Full Text] [PDF]